Molecular structure of Lenvatinib, CAS Number: 417716-92-8
Lenvatinib (CAS 417716-92-8)
See product citations (3)
Alternate Names:
4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide
Application:
Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors
CAS Number:
417716-92-8
Molecular Weight:
426.85
Molecular Formula:
C21H19ClN4O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Lenvatinib is a compound utilized primarily in research focused on its role as a multi-targeted receptor tyrosine kinase inhibitor. In laboratory applications, it is used to study cellular processes related to angiogenesis and the proliferation of cancer cells. Researchers employ Lenvatinib to understand the pathways involved in the regulation of vascular endothelial growth factor (VEGF) receptors, fibroblast growth factor (FGF) receptors, and platelet-derived growth factor (PDGF) receptors, among others. It is also a subject of interest in the investigation of the tumor microenvironment, specifically in understanding how the inhibition of these kinases can influence the network of signaling that contributes to tumor growth and metastasis.
Lenvatinib (CAS 417716-92-8) References
- Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. | Matsuki, M., et al. 2018. Cancer Med. 7: 2641-2653. PMID: 29733511
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. | Kimura, T., et al. 2018. Cancer Sci. 109: 3993-4002. PMID: 30447042
- Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. | Wang, DX., et al. 2020. World J Gastroenterol. 26: 4465-4478. PMID: 32874058
- STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib. | Zheng, Y., et al. 2021. J Hematol Oncol. 14: 16. PMID: 33446239
- Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. | Dierks, C., et al. 2021. Thyroid. 31: 1076-1085. PMID: 33509020
- Lenvatinib-related renal microangiopathy: a case series. | Delsante, M., et al. 2022. Virchows Arch. 480: 467-473. PMID: 33959820
- Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. | Deng, H., et al. 2021. J Immunother Cancer. 9: PMID: 34168004
- Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. | Adachi, Y., et al. 2022. Cancer Res. 82: 292-306. PMID: 34753772
- Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. | Shi, T., et al. 2021. Int J Mol Sci. 22: PMID: 34884875
- Integrin subunit beta 8 contributes to lenvatinib resistance in HCC. | Hou, W., et al. 2022. Hepatol Commun. 6: 1786-1802. PMID: 35238496
- Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. | Wu, CJ., et al. 2022. Cancer Immunol Immunother. 71: 2631-2643. PMID: 35347395
- Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma. | Iseda, N., et al. 2022. Cancer Sci. 113: 2272-2287. PMID: 35466502
- Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma. | Huang, S., et al. 2022. Int J Biol Sci. 18: 4357-4371. PMID: 35864956
- Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma. | Hu, B., et al. 2022. Cancer Res. 82: 3845-3857. PMID: 36066408
- METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma. | Huang, M., et al. 2023. Cancer Res. 83: 89-102. PMID: 36102722
Inhibitor of:
2900062L11Rik, 3110052M02Rik, 7420461P10Rik, AA987161, ALG11, ALK-1, AMBP, Angptl1, BAALC, BSPH1, Bu-b, CEACAM20, Cnpy1, Consortin, CT47B1, FAM75C2, FGF-BP3, FHL-5, FIBP, Fibroblast Growth Factor (FGF), Flk-1, FLTR1, GAPT, GFR-1, Gm14325, Gm3336, GPR172C, Hepatocellular Carcinoma Marker, HGFL α, HHCM, HSTF4, IgA1, L-Selectin, MAGE-C3, NET-2, neuropilin, Olr1029, Olr1059, Olr1061, Olr1063, Olr1126, Olr1169, Olr119, Olr1206, Olr1235, Olr1259, Olr1350, Olr1385, Olr1397, Olr1404, Olr1528, Olr1558, Olr1562, Olr157, Olr165, Olr170, Olr175, Olr223, Olr322, Olr348, Olr357, Olr363, Olr37, Olr390, Olr484, Olr517, Olr541, Olr559, Olr560, Olr569, Olr653, Olr668, Olr714, Olr72, Olr733, Olr736, Olr750, Olr773, Olr788, Olr87, Olr920, Olr943, Olr964, PATE-N, PIG-M, PTOV1, RASGEF1A, Renal Cell Carcinoma, Ret, RETL2, RGL1, RNF213, Rse, SEF14, SGS2, Sm D1, Srb4, TDF, TSHβ, TSHR, Vasohibin-2, VEGF, VEGF-D, VG5Q, VHR, Vmn2r52, and VSIG10.Activator of:
CEACAM6, Hec1, HGFL, PlGF, PRAT4B_Cnpy4, and Tie-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lenvatinib, 5 mg | sc-488530 | 5 mg | $178.00 | |||
Lenvatinib, 25 mg | sc-488530A | 25 mg | $648.00 | |||
Lenvatinib, 100 mg | sc-488530B | 100 mg | $1657.00 |